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Abstract
Background: There is interest in defining mouse neurobiological phenotypes useful for studying autism spectrum
disorders (ASD) in both forward and reverse genetic approaches. A recurrent focus has been on high-order
behavioral analyses, including learning and memory paradigms and social paradigms. However, well-studied mouse
models, including for example Fmr1 knockout mice, do not show dramatic deficits in such high-order phenotypes,
raising a question as to what constitutes useful phenotypes in ASD models.
Methods: To address this, we made use of a list of 112 disease genes etiologically involved in ASD to survey, on a
large scale and with unbiased methods as well as expert review, phenotypes associated with a targeted disruption
of these genes in mice, using the Mammalian Phenotype Ontology database. In addition, we compared the results
with similar analyses for human phenotypes.
Findings: We observed four classes of neurobiological phenotypes associated with disruption of a large proportion
of ASD genes, including: (1) Changes in brain and neuronal morphology; (2) electrophysiological changes; (3)
neurological changes; and (4) higher-order behavioral changes. Alterations in brain and neuronal morphology
represent quantitative measures that can be more widely adopted in models of ASD to understand cellular and
network changes. Interestingly, the electrophysiological changes differed across different genes, indicating that
excitation/inhibition imbalance hypotheses for ASD would either have to be so non-specific as to be not falsifiable,
or, if specific, would not be supported by the data. Finally, it was significant that in analyses of both mouse and
human databases, many of the behavioral alterations were neurological changes, encompassing sensory alterations,
motor abnormalities, and seizures, as opposed to higher-order behavioral changes in learning and memory and
social behavior paradigms.
Conclusions: The results indicated that mutations in ASD genes result in defined groups of changes in mouse
models and support a broad neurobiological approach to phenotyping rodent models for ASD, with a focus on
biochemistry and molecular biology, brain and neuronal morphology, and electrophysiology, as well as both
neurological and additional behavioral analyses. Analysis of human phenotypes associated with these genes
reinforced these conclusions, supporting face validity for these approaches to phenotyping of ASD models. Such
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Findings
Approach
T h e r ei so v e r w h e l m i n ge v i d e n c ef o rac r i t i c a lr o l ef o r
genetic variation in autism spectrum disorders (ASD)
[1,2]. Moreover, all of the genes and loci reliably identi-
fied to date are associated with significant risk, such
that genetically modified rodents recapitulating an ASD
gene defect will have strong construct validity for ASD.
There have been many such models created and we can
now ask which neurobiological domains are altered in a
recurrent manner when an ASD gene is disrupted. The
observed mouse phenotypes can then be related to
those observed in humans with a similar gene disruption
to assess face validity of rodent models for ASD.
I no r d e rt oa c h i e v et h e s eg o a l s ,w em a d eu s eo fm a n u -
ally curated lists of genes implicated in ASD. In contrast
to other studies, we focused on genes where there was
prior evidence of an etiological role in ASD (that is,
genes of major effect for ASD). We began with a carefully
curated list of 103 such genes implicated in ASD, with or
without intellectual disability (ID), from a recent review
by one of us (CB) [3]. In that study, an extensive litera-
ture search was conducted looking for articles describing
genetic disorders in patients with autism, ASD, pervasive
developmental disorder, Asperger syndrome, or autistic/
autistic-like traits/features/behavior, using PubMed and
Google Scholar, as well as follow-up of references cited
in the papers thus identified. This list has been routinely
updated by the author using the same criteria, and nine
additional genes were added to the published report
(DPYD, FOLR1, GNS, GRIN2B, HEPACAM, HGSNAT,
KCNJ11, NAGLU,a n dSTXBP1). The final list of 112
genes implicated in ASD (ASD112) is shown in Addi-
tional file 1. Since most high-risk ASD genes were identi-
fied by unbiased genetic approaches (for example,
characterization of translocation breakpoints, recurrent
copy number variants, X-linked genes first identified by
linkage, and so on), ASD112 represents a largely unbiased
list of such genes. As part of our analyses we made use of
three prior publications to identify 31 genes from the 112
that were identified in large-scale proteomic analyses of
human or mouse postsynaptic densities, or mouse presy-
naptic or postsynaptic proteomes [4-6]. These 31 genes
are referred to as synaptic ASD genes (ASD31 in addi-
tional file 1). While there are likely additional synaptic
genes in ASD112 that were not included in ASD31 (for
example, NLGN4X), we chose to identify synaptic genes
using empirical proteomic datasets such that this list
would remain unbiased by genes chosen for further
detailed study.
We then took these two ASD gene lists and used them
to identify significantly enriched categories of mouse and
human phenotypes from the Mammalian Phenotype
Ontology (MPO) project [7], using ToppGene [8]. We
used the hypergeometric test to exactly calculate P values
for enrichment and further required that the Bonferroni
corrected P value be < 0.01. We made use of the standard
hypergeometric approach defining the hypergeometric
probability, h(x; N, n, k), as {[kCx][N-kCn-x]}/[NCn], where
N is the number of annotated genes in the genome, k is
the number of genes in the genome that are associated
with a given phenotype or other category, n is the num-
ber of genes in the test list (for example, ASD112), x is
the number of genes in the test list that have the given
phenotype or other category, and kCx represents the
number of combinations of k things, taken x at a time.
This approach ensures that the findings we describe are
quantitative and statistically substantiated, while also
being conservative (as we use an analysis-wide Bonferroni
correction).
Enriched mouse phenotype (MP) categories
We asked whether known ASD disease genes could be
used to provide insights into defined murine pheno-
types. Using the entire ASD gene list, we identified 60
categories significantly enriched in the mouse phenotype
categories after correction (Figure 1 and Additional
file 2). Of the 60 categories, 23 were directly related to
alterations in brain or neuronal morphology (note the
coloration of bars in Figure 1), with an additional eight
categories associated with other morphological changes.
A further 21 categories related to changes in observable
behaviors. However, most behavioral findings reflected
alterations in neurological processes (MP categories, from
lowest P value and up were: MP:0002066, abnormal motor
capabilities/coordination/movement; MP:000206, abnor-
mal sensory capabilities/reflexes/nociception; MP:0003313
abnormal locomotor activation; MP:0002064, seizures;
MP:0001961, abnormal reflex; MP:0001392, abnormal
locomotor activity; MP:0000947, convulsive seizures;
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involuntary movement; MP:0003491, abnormal voluntary
movement; MP:0001516, abnormal motor coordination/
balance; MP:0001405, impaired coordination) with a smal-
ler number reflecting deficits in high-order processes
(MP:0001449, abnormal learning/memory; MP:0002063,
abnormal learning/memory/conditioning; MP:0001463,
abnormal spatial learning; MP:0002062, abnormal condi-
tioning behavior; MP:0002065, abnormal fear/anxiety-
related behavior; MP:0001454, abnormal cued condition-
ing behavior; MP:0001363, increased anxiety-related
response; MP:0004924, abnormal behavior).
Three enriched terms related to electrophysiology and
neuronal transmission (MP:0003635, abnormal synaptic
transmission; MP:0003633, abnormal nervous system
physiology; and MP:0002206, abnormal CNS synaptic
transmission) providing further objective support for the
important role of electrophysiological analyses in under-
standing pathophysiology in ASD. Note that there were
over 40 genes associated with changes in electrophysiol-
ogy and neuronal transmission (see below) and that
these changes were quite diverse, including enhanced
hippocampal long-term potentiation and long-term
depression as well as deficits or no changes in these
measures.
Related to the electrophysiological deficits were the cate-
gories associated with seizure disorders (MP:0002064, sei-
zures; MP:0000947, convulsive seizures; MP:0003216,
absence seizures; MP:0000948, non-convulsive seizures)
and sensory and motor abnormalities (MP:0002066,
Figure 1 Mouse phenotype categories associated with ASD genes. ASD genes (n = 112) were analyzed for enrichment in mouse
phenotypes using ToppGene with a Bonferroni corrected P value cutoff of 0.01. Categories are arranged from most significant and downwards
(purple line), and for each category, the number of genes in the ASD112 list for which there were murine models with the associated category
are indicted by the length of the horizontal bars (gene count). To highlight differing phenotypic categories discussed in the text, bars are color-
coded as indicated in the inset to the figure. Categories relating to nervous system morphology phenotype domains are colored light blue,
while other morphological categories are colored dark blue, electrophysiological categories are colored pink, neurological categories are colored
peach, and higher-order behavioral categories are colored green. Categories corresponding to more than one phenotyping domain are
presented as alternating colors, and categories that do not relate to our phenotyping scheme are colored yellow. All data are also found in
tabular form in Additional file 2.
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MP:000206, abnormal sensory capabilities/reflexes/noci-
ception; MP:0003313, abnormal locomotor activation;
MP:0001961, abnormal reflex; MP:0001392, abnormal
locomotor activity; MP:0003492, abnormal involuntary
movement; MP:0003491, abnormal voluntary movement;
MP:0001516, abnormal motor coordination/balance;
MP:0001405, impaired coordination).
Similar conclusions can be made from the synaptic
ASD genes (Figure 2 and Additional file 3). Eleven out of
the eighteen significant terms related to alterations in
brain and neuronal structure, three terms related to elec-
trophysiology and synaptic transmission (MP:0003635,
abnormal synaptic transmission; MP:0003633, abnormal
nervous system physiology; and, MP:0002206, abnormal
CNS synaptic transmission) and three terms related to
behavioral changes (MP:0001463, abnormal spatial learn-
ing; MP:0002063, abnormal learning/memory/condition-
ing; and, MP:0001449, abnormal learning/memory).
Enriched human phenotype (HP) categories
One can also ask what human phenotypes are enriched
with these ASD genes. Although the genes have been
collated because of their role in ASD, an unbiased view
can provide an assessment of the fuller spectrum of
associated phenotypes as well as the relationship of
these phenotypes to the enriched mouse phenotypes.
We identified 151 significantly enriched categories
(Additional file 4); the top 80 are shown in Figure 3.
Interestingly, we observed significant overlaps in human
and mouse phenotypes associated with ASD genes. Using
the full ASD gene list, there was direct evidence for
changes in brain morphology (HP:0002060, abnormality of
the cerebrum; HP:0002977, aplasia/hypoplasia involving
the central nervous system; HP:0007364, aplasia/hypopla-
sia of the cerebrum; HP:0001273, abnormality of the cor-
pus callosum; HP:0007370, aplasia/hypoplasia of the
corpus callosum; HP:0000252, microcephaly; HP:0000256,
macrocephaly; HP:0002118, abnormality of the cerebral
ventricles; HP:0002119, ventriculomegaly; HP:0001339, lis-
sencephaly; HP:0002059, cerebral atrophy; HP:0007369,
atrophy/degeneration affecting the cerebrum). There was
also indirect evidence for alterations in brain morphology
given the very extensive numbers of categories affecting
craniofacial morphology.
Electrophysiological deficits are not systematically assessed
in patients with ASD, but there was evidence for such
changes associated with many ASD genes (HP:0001311,
neurophysiological abnormality; HP:0001250, seizures;
HP:0002353, EEG abnormalities). Furthermore, there
was extensive evidence for neurological abnormalities in
these analyses. In addition to the brain morphology and
Figure 2 Mouse phenotype categories associated with synaptic ASD genes. Thirty-one ASD genes (ASD31) found in the synaptic proteome
were analyzed for enrichment in mouse phenotypes using ToppGene with a Bonferonni corrected P value cutoff of 0.01. Further details
regarding the figure and inset are described in the legend to Figure 1. All data are also found in tabular form in Additional file 3.
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gories included: HP:0000707, neurological abnormality;
HP:0000496, abnormality of eye movement; HP:0001252,
muscular hypotonia; and, HP:0001270, motor retardation.
Behavior findings included: HP:0001249, mental retarda-
tion; HP:0000752, hyperactivity; HP:0000717, autism;
HP:0006887, mental retardation, progressive; HP:0002360,
sleep disturbances; HP:0000718, aggressive behavior;
HP:0000735, impaired social interactions; HP:0002117,
speech delay; HP:0002116, deficiency of speech develop-
ment; HP:0000733, stereotyped, repetitive behavior;
HP:0002456, severe behavioral problems at age 3 to 4 years;
HP:0000748, inappropriate laughter; and HP:0000749, par-
oxysmal bursts of laughter.
Implications for phenotyping rodent models for ASD
Based on our analyses, we propose five broad categories
of analysis for rodent models of ASD, including bio-
chemical and molecular analyses using both targeted
and genome-level approaches (which are not captured
in the MP databases) and the four domains we identify
in our analyses (Table 1). We can further assess specific
Figure 3 Human phenotype categories associated with ASD genes. ASD genes (n = 112) were analyzed for enrichment in human
phenotypes using ToppGene with a Bonferonni corrected P value cutoff of 0.01. This figure only shows the first 80 categories ranked from most
significant P value; the full list of 151 significant categories is found in tabular form in Additional file 4. Further details regarding the figure and
inset are described in the legend to Figure 1.
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findings to date. To do this, we took the top 10 (based
on P values) categories for morphology (Additional
file 5) or behavior (Additional file 6), and all three top
categories for electrophysiology (Additional file 7), and
surveyed the literature on phenotypes in mice with a
targeted disruption of the gene.
Examining ASD genes associated with morphological
changes, we can see that brain abnormalities occur gener-
ally among three major categories: (1) major developmen-
tal pathologies of the neuraxis (13 genes); (2) alterations in
the development of specific regions of the brain with
abnormal migration of neurons as well as glial cells (15
genes); and (3) alteration of neuronal morphologies and
anomalies of dendritic spines and synapses (21 genes).
The morphologic characterization of the first category of
abnormalities may lend itself to simple analyses of gross
pathology as well as magnetic resonance microscopy,
while the second and third categories would involve quan-
titative analyses of neuronal fate and neuronal migration
at the level of specific populations of precursors, tract-tra-
cing using diffusion tensor imaging, and assessment of
neuronal morphology, dendritic and spine integrity at the
single spine level of resolution, and electron microscopy of
synaptic morphology and distribution of specific synaptic
markers using immunoelectron microscopy methods. The
data obtained by such approaches can then be correlated
to electrophysiological and behavioral data.
Electrophysiological findings in mouse models amongst
the over 40 ASD genes surveyed fell into two broad
areas: (1) changes in evoked field potentials measured by
extracellular recording in brain slices; and (2) changes in
ion channel function measured by patch-clamp record-
ings in brain slices. Brain regions examined were hippo-
campus, neocortex, cerebellum, and amygdala. For the
evoked potentials, analyses included those for basal
synaptic properties, short-term plasticity (using the
paired-pulse paradigm), long-term plasticity (with induc-
tion of long-term potentiation by high-frequency or
theta-burst stimulation, or induction of long-term
depression by low-frequency stimulation), and seizure-
like activity (using low Mg
2+). Patch-clamp recordings
focused on basic membrane properties, characterization
of voltage-gated (Na
+,K
+,C a
2+) and ligand-gated
(NMDA, AMPA, GABA) ion channel currents, and
assessment of spontaneous neurotransmission (sponta-
neous miniature inhibitory and excitatory events by mea-
suring inhibitory and excitatory post-synaptic currents).
Behavioral analyses were quite diverse in the papers
reviewed but, based on analysis of positive findings, we
can propose the following. For neurological changes,
observing spontaneous and elicited behaviors with proto-
cols such as the SHIRPA protocol are appropriate, includ-
ing an assessment of grip strength, sensitivity to pain (for
example, tail flick), gait analysis, accelerating rotarod,
acoustic startle, prepulse inhibition of acoustic startle, and
seizure susceptibility (spontaneous, drug-induced, auditory
evoked). For high-order behaviors, we would include
assessment of anxiety (for example, elevated zero maze
and open field), spontaneous locomotor behavior, social
interaction/recognition, cued and contextual fear condi-
tioning, Morris water maze, radial arm maze, passive
avoidance, observation for stereotyped behaviors, and
ultrasonic vocalizations. These recommendations are
Table 1 Recommended assays for ASD-related changes in rodent models
Levels of analysis Specific assays
Molecular assays Focused biochemical and molecular assays directed at the targeted gene and pathway
Unbiased proteomic and genome-wide gene expression analysis, with pathway and network analysis
Nervous system morphology
assays
Gross pathology
Analyses of neuronal fate and neuronal migration including tract-tracing
Assessment of neuronal morphology, dendritic and spine integrity, and synaptic morphology
Electrophysiological assays Use of evoked field potentials to assess basal synaptic properties, short-term plasticity, long-term plasticity, and
analysis of seizure-like activity
Patch-clamp recording for basic membrane properties, characterization of voltage- and ligand-gated ion channel
currents, and assessment of spontaneous neurotransmission
Neurological assays General observations, spontaneous and elicited behaviors
Assessment of grip strength, sensitivity to pain, gait, accelerating rotarod, acoustic startle, and prepulse inhibition of
acoustic startle
Analysis of seizure susceptibility
Higher-order behavioral
assays
Assessment of anxiety, open field/spontaneous locomotor behavior
Analysis of social interaction/recognition, including ultrasonic vocalizations
Assessment of learning and memory, including cued and contextual fear conditioning, Morris water maze, radial arm
maze, and passive avoidance
Recording of behavioral stereotypes
Based on a survey of findings, we conclude that five levels of analysis should be carried out on rodent ASD models. Four are derived from the unbiased
enrichment analyses described in the main text and the fifth (molecular) is part of the standard and enhanced workup of novel model systems. In each of the
five domains, specific assays are suggested, based on expert review of publications of at least 40 genes associated with electrophysiological, neurological, or
higher behavioral features.
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relevant to ASD [9].
Conclusions
ASD are defined by alterations in a triad of symptom
domains, including impairments in social interactions,
impairments in language or the social use of language,
and by restricted, repetitive, and stereotyped patterns of
behaviors and interests. A significant challenge to analyz-
i n gA S Di nh u m a n si st h er e s t r i c t e dt o o l sa v a i l a b l ef o r
studying the human brain. For this reason, animal models
provide a critical means to understand pathophysiology
and identify therapeutic opportunities. As noted above,
because there are known, high-risk, ASD genes, rodent
model systems can be developed with strong construct
validity for ASD. As we begin to assess novel therapeutics
in ASD, determining which phenotypes in rodents have
face and ultimately predictive validity in ASD becomes
an important aim. Many attempts have been made to
describe rodent phenotypes that fall within the ASD triad
in order to establish face validity. This study differs from
such recent studies in that rather than asking what beha-
viors in rodents might reflect the core features of ASD,
we asked what phenotypes in rodents were observed in
mice with disruptions in diverse ASD causal genes. This
provides an unbiased assessment of ASD phenotypes
associated with these genes. We also carried out a simi-
lar, unbiased analysis of phenotypes in patients with dis-
ruptions in ASD genes and showed that the categories
outside of the core ASD behavioral triad were similarly
impacted in both the mouse and human analyses. This
provides important face validity to the analyses.
In spite of the fact that high-risk ASD genes analyzed
in the current report impact a large number of pathways
(Additional file 8), an unbiased assessment of murine
phenotypes associated with ASD genes shows clear evi-
dence for effects on brain and neuronal morphology,
electrophysiology, neurological features, and high-order
behavior. In addition, the analyses indicate that beha-
vioral deficits in ASD models are frequently not in social
domains, supporting a broad examination of neurological
as well as high-order behavioral paradigms to support a
neurodevelopmental function for the gene under study. It
also suggests that forward genetics, starting from a deficit
in high-order behaviors, may obscure many important
genes and pathways. Electrophysiological changes dif-
fered across different ASD genes and in differing direc-
tions, indicating that the excitation/inhibition imbalance
hypothesis is not specific or is too broad as to be not
falsifiable.
Caveats with the current approach are that not all ana-
lyses have been applied to all mouse models and even if
similar approaches were used they were not always iden-
tically applied. Moreover, we did not explicitly catalog
models with disruptions in high-risk ASD genes where
specific phenotypes were not observed. Finally, the MPO
database is incomplete and biases might be introduced by
choices of genes to study and disrupt, and by phenotyp-
ing choices.
One can argue that amongst the four broad categories
identified in unbiased analyses, morphological and electro-
physiological alterations are most proximal to changes in
gene expression, and may then impact on seizure risk and
alterations in sensory and motor function, followed by
effects on high-order behaviors. In this view, a focus on
low-order processes may be more informative than a focus
on high-order processes. This is a departure from recent
recommendations in that we conclude that the data argue
for a strong bottom-up approach to phenotyping rodent
models of ASD. Certainly, in the case of several ongoing
clinical trials for monogenic forms of ASD, including
Fragile X syndrome, tuberous sclerosis, and Rett syn-
drome, molecular, morphological, and electrophysiological
analyses were key parts of target identification and even
preclinical studies, as were behavioral phenotypes.
Altogether, these results highlight how basic neu-
roscience approaches in model systems identify relevant
and important phenotypes that will continue to shed
light on ASD pathophysiology at multiple levels.
Additional material
Additional file 1: Gene lists. Excel file containing the lists of the 112
ASD genes and the 31 synaptic ASD genes.
Additional file 2: Mouse phenotype categories associated with ASD
genes. Excel file with the enrichment analysis of mouse phenotypes
using as the seed list 112 ASD genes (Additional file 1). Columns are
mouse phenotype (MP) ID, MP name, enrichment P value, Term in Query,
and Term in Genome (number of genes in the murine genome that
were associated with that MP category at the time of the analysis).
Additional file 3: Mouse phenotype categories associated with
synaptic ASD genes. Excel file with enrichment analysis of mouse
phenotypes using as the seed list 31 synaptic ASD genes (Additional file
1). See legend for Additional file 2 for explanation of column headers.
Additional file 4: Human phenotype categories associated with ASD
genes. Excel file with enrichment analysis of human phenotypes using as
the seed list 112 ASD disease genes (Additional file 1). Columns are
human phenotype (HP) ID, HP name, enrichment P value, Term in Query
and Term in Genome. See legend for Additional file 2 for explanation of
column headers.
Additional file 5: Genes in the top 10 mouse phenotype
morphology categories. Excel file with the genes found in the top 10
categories relating to morphological abnormalities associated with
mouse mutations in ASD genes. The seed list used was the 112 ASD
genes. For each category, columns indicate Entrez Gene ID, Gene
Symbol, and Gene Name.
Additional file 6: Genes in the top 10 mouse phenotype behavioral
categories. Excel file with the genes found in the top 10 categories
relating to behavioral abnormalities associated with mouse mutations in
ASD genes. See Additional file 5 legend for more information.
Additional file 7: Genes in the top mouse phenotype
electrophysiological categories. Excel file with the genes found in the
top (n = 3) categories relating to electrophysiological abnormalities
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legend for more information.
Additional file 8: Gene Ontology categories associated with ASD
genes. Excel file with the enrichment analysis of Gene Ontology (GO)
categories using as the seed list 112 ASD genes (Additional file 1).
Columns are GO, GO name, enrichment P value, Term in Query, and
Term in Genome.
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